Clinical Trial Update: SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SKB264 plus Inetetamab in HER2-positive metastatic breast cancer patients progressing after T-DXd treatment; status is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Inetetamab (inetetamab)
• SKB264

Snippet

Sponsor: Fudan University | Conditions: HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264 | Phase 2 | Status: RECRUITING